Dec 05 2025 This Week in Cardiology

Less is more after PCI, the TARGET-FIRST trial, a negative blood pressure trial that is actually positive, aspirin vs OAC for bleeding, AEDs, and Factor XI is not dead yet are the topics discussed by John Mandrola, MD, on this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Less is More: TARGET-FIRST
TARGET-FIRST Trial https://www.nejm.org/doi/10.1056/NEJMoa2508808
STOPDAPT-2 ACS Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2789701
II A Negative Trial That Is Actually Positive
The RETREAT-FRAIL Study https://www.nejm.org/doi/full/10.1056/NEJMoa2508157
III Major Bleeding With Aspirin vs Apixaban
Subanalysis of ARTESiA https://jamanetwork.com/journals/jamacardiology/fullarticle/2841075
ARTESiA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2310234
AVERROES Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1007432
IV High Value Interventions – The AED
Experts Call for AED Placement on All Commercial Aircraft https://www.medscape.com/viewarticle/experts-call-aed-placement-all-commercial-aircraft-2025a1000xzf
In-Flight Sudden Cardiac Arrest and AED Use 10.1016/j.cjca.2025.10.010 External Link
V Factor XI Inhibitors – OCEANIC STROKE trial
Bayer Press Release on Asundexian https://www.bayer.com/en/us/news-stories/oceanic-stroke
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.